This clinical trial is for men and women age 18 and older with previously treated CLL/SLL, MCL, FL, MZL, DLBCL, or RTL. Relapsed or refractory hematological cancers are serious, disabling, and life-threatening disorders. Existing therapies can induce prolonged regressions but typically lose effectiveness over time. New therapies with new mechanisms of action are needed to overcome disease resistance and improve outcomes.
ROR1 expression offers a cancer-specific marker in several hematological cancers. Through selective targeting of ROR1-positive tumor cells, VLS-101 may safely improve clinical outcomes for patients with previously treated hematological cancers. The potential for beneficial clinical efficacy of VLS-101 against ROR1-positive cancers is well founded on evaluation of its therapeutic effects in relevant in vitro and in vivo efficacy models.
The purpose of this study is to determine the maximum tolerated dose and/or recommended dosing regimen of VLS-101 in previously treated hematological malignancy patients.